CLAIMS

1. Use of aAn attenuated mutant strain of Salmonella comprising at least one copy of a recombinant DNA molecule comprising an expression cassette encoding Mesothelin (MSLN) for the manufacture of a vaccine for cancer immunotheraphy.

2. The ~~attenuated mutant strain of Salmonella~~use of claim 1, wherein the attenuated mutant strain of Salmonella ~~is of the species Salmonella enterica, particularly wherein the attenuated mutant strain of Salmonella~~ is Salmonella typhi Ty21a.

3. The ~~attenuated mutant strain of Salmonella~~use of claim 1 or 2, wherein the expression cassette is a eukaryotic expression cassette.

4. The ~~attenuated mutant strain of Salmonella~~use of any one of claims 1 to 3, wherein MSLN is ~~selected from the group consisting of~~ human MSLN ~~and a protein that shares at least 80% sequence identity therewith, particularly wherein MSLN has~~having the amino acid sequence as found in SEQ ID NO 1.

5. The ~~attenuated mutant strain of Salmonella~~use of claim 3 or 4, wherein the recombinant DNA molecule comprises the kanamycin antibiotic resistance gene, the pMB1 ori, and a eukaryotic expression cassette encoding human MSLN ~~or a protein that shares at least 80% sequence identity therewith~~ under the control of a CMV promoter, ~~particularly~~ wherein human MSLN has the nucleic acid sequence as found in SEQ ID NO 2.

~~6. The attenuated mutant strain of Salmonella of any one of claims 1 to 5 for use as a medicament.~~

~~7. The attenuated mutant strain of Salmonella of claim 6 for use as a vaccine.~~

~~8. The attenuated mutant strain of Salmonella of claim 7 for use in cancer immunotherapy.~~

~~9.~~6. The ~~attenuated mutant strain of Salmonella~~use of any one of the preceding claim~~s 8~~, wherein cancer immunotherapy further comprises administration of one or more further attenuated mutant strain(s) of Salmonella comprising at least one copy of a recombinant DNA molecule comprising an expression cassette encoding a tumor antigen and/or a tumor stroma antigen~~, particularly wherein said one or more further attenuated mutant strain(s) of Salmonella is/are Salmonella typhi Ty21a comprising a eukaryotic expression cassette, more particularly wherein said one or more further attenuated mutant strain(s) of Salmonella comprise(s) an attenuated mutant strain of Salmonella encoding human VEGFR-2 and/or human Wilms' Tumor Protein (WT1).~~

7. The use of claim 6 wherein said one or more further attenuated mutant strain(s) of Salmonella comprise(s) an attenuated mutant strain of Salmonella encoding human VEGFR-2 and/or human Wilm's Tumor Protein (WT1).

~~10.~~8. The ~~attenuated mutant strain of Salmonella~~use of ~~any of the preceding claims, in particular according to~~ claim~~s~~ 6 or ~~7~~9, wherein the attenuated mutant strain of Salmonella is co-administered with said one or more further attenuated mutant strain(s) of Salmonella.

~~11.~~9. The ~~attenuated mutant strain of Salmonella~~ use of any one of claims 1 to ~~8 to 10~~, wherein cancer immunotherapy is accompanied by chemotherapy, radiotherapy or biological cancer therapy~~, particularly wherein the attenuated mutant strain of Salmonella is administered before or during the chemotherapy or the radiotherapy treatment cycle or before or during biological cancer therapy, or before and during the chemotherapy or the radiotherapy treatment cycle or the biological cancer therapy~~.

~~12.~~10. The ~~attenuated mutant strain of Salmonella~~ use of any one of claims ~~6 to 11~~ to 9, wherein the attenuated mutant strain of Salmonella is administered orally.